Urine DNA methylation detection, bladder cancer can be screened in the future

Text/Tuyang City Evening News all -media reporter Zhang Hua correspondent Lin Weiyin

Urine DNA methylation non -invasive diagnostic bladder cancer is already in clinical application, single -hole laparoscopic surgery robot system is being approved to be listed in the national CFDA, AI urine lone cytology technology screening bladder cancer ... On August 13, the reporter was "2022, 2022 The Guangdong Medical Society of Medical Association and the China Bladder Cancer Summit Forum in 2022 "Bladder Cancer Forum" was informed that the current early discovery, diagnosis and treatment technology of bladder cancer have made great breakthroughs.

Huang Jian, chairman of the Chinese Medical Association's Urology Science Branch, Huang Jian, a professor of urology at Sun Yaxian Memorial Hospital of Sun Yat -sen University

Huang Jian, chairman of the Chinese Medical Association's Urology Science Branch and Professor Huang Jian, a professor of urology at Sun Yaxian Memorial Hospital of Sun Yat -sen University, said in an interview with reporters that although the incidence of bladder cancer in my country has gradually increased, with the progress of the times and the common efforts of the majority of urological doctors The level of bladder cancer diagnosis and treatment has improved significantly and improved, and the mortality rate of bladder cancer has been effectively controlled.

Urine DNA methylation detection is expected to screen bladder cancer in the future

At present, the incidence of bladder cancer in the incidence of male urinary tumors in my country ranks second (the first is prostate cancer), with 80,000 new bladder cancer patients each year. The incidence of bladder cancer is growing year by year. According to statistics, the incidence of bladder cancer in my country has reached 58/100,000, and the incidence of men is higher than women.

Chairman of the Guangdong Medical Association of the Urology Science Branch and Lin Tianyi, a professor of urology at Sun Yaxian Memorial Hospital Sun Yixian Memorial Hospital of Sun Yat -sen University

At present, as far as the diagnosis and postoperative monitoring of bladder cancer, cystoscopy+pathological biopsy as a "gold standard" is a creative examination method. "Every time you make a cystoscope for patients and enter the bladder from the urethra, it often makes patients feel pain, and there is also the possibility of damage to the urology tissue during the operation." Lin Tianyi, a professor of urology at Sun Yixian Memorial Hospital, said that in order to make the diagnosis of bladder cancer more convenient and reduce the pain of patients, Sun Yixian Memorial Hospital of Sun Yat -sen University took the lead in developing a new technique for the diagnosis of bladder cancer -urine Urify. Clinical studies have shown that the overall accuracy of the methylation detection model is more than 87%, and the sensitivity is more than 92.0%.

"People with painless hematuria need only 50 ml of urine. Cancer cells can be found with urine DNA methylation testing, so as to detect and diagnose bladder cancer early." Lin Tianyi said.

It is reported that this diagnostic method is suitable for patients with bladder cancer or patients who cannot detect extremely early imaging tests or patients who are suspected of urinary tract ureteral tumors. At the same time, patients who need regular cystoscopy after bladder cancer can also be used to reduce the number of cystoscope examinations and reduce the pain of patients.

According to the reporter's understanding, the current urine DNA methylation test requires 2,000 yuan. Lin Tianzheng said that although the current urine DNA methylation testing is mainly auxiliary diagnosis of bladder cancer for patients with painless hematuria, it is also expected to popularize the scheme and screen for bladder cancer in the future.

Minimally invasive surgery is a trend of bladder cancer surgery

Bladder cancer surgery minimally invasive technology singing protagonist, domestic single -hole laparoscopy robot will soon go public

At present, surgical therapy represented by urethral bladder tumor cutting and radical bladder resection is still the most important part of the comprehensive treatment of bladder cancer, but the surgical method has changed from open to minimally invasive surgery. This is bladder cancer. This is bladder cancer. This is bladder cancer. The trend of surgery.

Huang Jian, chairman of the Chinese Medical Association's Urology Science Branch and a professor of urology at Sun Yaxian Memorial Hospital of Sun Yat -sen University, said that at present, most of the three hospitals in my country have basically used minimally invasive surgery to impose a cure resection surgery for patients with bladder cancer, such as Minimally invasive means and other means of laparoscopy, robotics, etc. "The main advantage of minimally invasive surgery is that the wound is small, less bleeding, and the patient's recovery is faster."

Professor Huang Jian also revealed that at present, Sun Yaxian Memorial Hospital of Sun Yat -sen University has successfully completed the R & D and setting of the single -hole laparoscopic surgery robot system. It is being approved to be listed in the near future through the national CFDA and EU CE inspection standards. "Because the single -hole laparoscopic robot system is higher than the porous robot system, after using a single -hole laparoscopic robot system, the robot's arm can be used like crabs. Multiple arms are performed surgery, so as to make the surgery more accurate." It is reported that the use of domestic single -hole laparoscopic robot system surgery clinically will be much cheaper than imported similar robot surgery. It can be said that this is also the problem of "stuck neck" in high -end medical equipment, especially laparoscopic equipment.

Bladder cancer surgery can also use a laparoscopic robot system for surgery

Bladder cancer research collaboration group promotes the "homogeneity" diagnosis and treatment of bladder cancer

In recent years, the incidence of bladder cancer has increased year by year, recurrence and mortality have remained high. To this end, Professor Huang Jian, Sun Yixian Memorial Hospital of Sun Yat -sen University in 2013, led the establishment of the China Bladder Cancer Alliance (CBCC) (now renamed the research and collaboration group of bladder cancer). The path to the diagnosis and treatment of different bladder cancer.

According to Professor Huang Jian, in the past ten years, CBCC has developed from the initial 40 member units to 214 member units, including provincial, cities, and counties.At the same time, CBCC has organized a series of national multi -center forward -looking RCT and real -world research, such as the research status of Chinese bladder cancer diagnosis and treatment.Frequent rumors, academic influence is increasing.Source | Yangcheng Evening News · Yangcheng School

Responsible | Niu Zhijie

School pair | He Qiyun

- END -